These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 24392303

  • 1. Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden.
    Flodmark CE, Lilja K, Woehling H, Järvholm K.
    Biol Ther; 2013; 3(1):35-43. PubMed ID: 24392303
    [Abstract] [Full Text] [Related]

  • 2. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R, Bidlingmaier M, Kreitschmann-Andermahr I, Land C, Partsch CJ, Schwab KO, Sommer H, Backeljauw P, Kanumakala S, Loche S, Zouater H, Strasburger CJ.
    Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319
    [Abstract] [Full Text] [Related]

  • 3. Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System.
    Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, Muenzberg M, Rapaport R.
    Biol Ther; 2014 Dec; 4(1-2):27-39. PubMed ID: 25096555
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study.
    Iughetti L, Tornese G, Street ME, Napoli F, Giavoli C, Antoniazzi F, Stagi S, Luongo C, Azzolini S, Ragusa L, Bona G, Zecchino C, Aversa T, Persani L, Guazzarotti L, Zecchi E, Pietropoli A, Zucchini S.
    Ital J Pediatr; 2016 Nov 03; 42(1):93. PubMed ID: 27809913
    [Abstract] [Full Text] [Related]

  • 5. Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study.
    Loche S, Kanumakala S, Backeljauw P, Schwab KO, Lechuga-Sancho AM, Esmael A, Urosevic D, Boldea A, Zabransky M.
    Drug Des Devel Ther; 2024 Nov 03; 18():667-684. PubMed ID: 38454934
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data.
    Backeljauw P, Kanumakala S, Loche S, Schwab KO, Miller BS, Levy R, McCormick K, Zouater H, Zabransky M, Campbell K.
    Eur J Pediatr; 2022 Jun 03; 181(6):2367-2378. PubMed ID: 35275291
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M, Malickova K, Kolar M, Bortlik M, Vasatko M, Machkova N, Hruba V, Duricova D, Lukas M.
    J Crohns Colitis; 2020 Jul 30; 14(7):915-919. PubMed ID: 31905382
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.
    Iughetti L, Antoniazzi F, Giavoli C, Bona G, Aversa T, Greggio NA, Guazzarotti L, Minelli R, Perrone L, Persani L, Pozzobon G, Ragusa L, Stagi S, Tornese G, Zecchino C, Gallinari P, Zouater H, Fedeli P, Zucchini S.
    J Endocrinol Invest; 2021 Mar 30; 44(3):493-503. PubMed ID: 32557273
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data.
    Romer T, Zabransky M, Walczak M, Szalecki M, Balser S.
    Biol Ther; 2011 Mar 30; 1(1):5. PubMed ID: 24392295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.